Company Overview
Product
Research & Development
Investor Relations
Company Overview
Product
Research & Development
Investor Relations
Address : 10F EK-Tower., 407 Teheran-ro, Gangnam-gu, Seoul (30M from Seolleung Station Exit #10 (towards Samsung Station)
TEL : 02-577-7667 FAX : 02-566-6003
Address : 13-39 Jeyakdanji-ro, Hyangnam-eup, Manse-gu, Hwaseong-si, Gyeonggi-do
TEL : 031-366-5511~5 FAX : 031-366-5510
Address :133, Jeyakgongdan 3-gil, Hyangnam-eup, Manse-gu, Hwaseong-si, Gyeonggi-do
TEL : 031-353-5883 FAX : 031-353-2472
Address : 57, Changeop-ro, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea
TEL : 031-698-3832 FAX : 031-698-3842
Hana Pharm’s head office is located in Gangnam-gu, Seoul and executes essential tasks such as development and finance to promote products effectively. Departments such as Marketing, Development, General Affairs, Finance, and Planning all cooperate together for the best efficiency. 13 sales offices in locations such as Seoul, Dae-jeon, Busan, Gwang-ju, and Jeju strive for sales excellence.
Hana Pharmaceutical Co., Ltd. completed construction of its 25 billion won Hagil Plant in June 2007. Optimized for stringent pharmaceutical production standards, the state-of-the-art facility aligns with Hana Pharmaceutical's corporate philosophy of contributing to the advancement of national health through the production of superior quality pharmaceuticals.
The Hagil Plant can produce solid dosage forms such as tablets and capsules, as well as injectable formulations such as ampoules, vials, and prefilled syringes. The entire pharmaceutical production process is strictly managed.
The new injection facility, completed in July 2025, produces liquid injections, lyophilized injections, and BFS (Blow Fill Seal) injections. Built as a high-quality pharmaceutical production base for exports to advanced markets, it features an advanced quality management system and equipment, and is used as a production base for injectable products, including the new anesthetic drug "Bypavo Injection."
In February 2025, the facility received EU-GMP approval from the European Medicines Agency (EMA) as a non-generic new drug. In June 2025, it received Japanese PMDA approval and is now exporting to Japan and Europe.
In 1985, Hana Pharm purchased a lot in the Hyangnam Pharmaceutical Complex, a major production area of the domestic pharmaceutical industry. We completed the current Sangshin factory at the level of KGMP (Korean Good Manufacturing Practice) that produces solid dosage forms and capsules in 1988 and were designated as a KGMP qualified company by MFDS in 1991. This allowed the company to be devoted to the production of excellent medicines through advanced equipment and manpower.
In 1997, We expanded the factory after getting KGMP certification, and finished remodeling to become synthesis and manufacturing plant in 2011 December. So, we had foundation to export excellent raw material globally synthesizing our own technology.
The Pangyo R&D Center is spearheading Hana Pharmaceutical's growth as a research-driven company. The Pangyo Research Center, which houses the New Drug Research Lab, Pharmaceutical Synthesis Lab, and Quality Research Lab, collaborates with leading research institutions to conduct specialized research on DDS-based limited-dose new drugs and anti-cancer drugs.